연구성과로 돌아가기
2020 연구성과별 연구자 정보 (63 / 2428)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Yoon, Seung Kew | Yoon, SK | 7 | Catholic Univ Korea, Dept Internal Med, Seoul, South Korea | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Kao, Jia-Horng | Kao, JH | 8 | Natl Taiwan Univ Hosp, Div Gastroenterol & Hepatol, Taipei, Taiwan | AAB-8947-2019 | KAO, JIA-HORNG | 0000-0002-2442-7952 | KAO, JIA-HORNG | pietro.lampertico@unimi.it; | |
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Chen, Chi-Yi | Chen, CY | 9 | Chia Yi Christian Hosp, Chiayi, Taiwan | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Tam, Edward | Tam, E | 10 | LAIR Ctr, Vancouver, BC, Canada | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Khalili, Mandana | Khalili, M | 11 | Univ Calif San Francisco, San Francisco, CA 94143 USA | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Bae, Ho | Bae, H | 12 | St Vincents Med Ctr, Los Angeles, CA USA | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Ma, Xiaoli | Ma, XL | 13 | Drexel Univ, Coll Med, Philadelphia, PA USA | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Tak, Won Young | Tak, WY | 14 | Kyungpook Natl Univ, Coll Med, Daegu, South Korea | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Flaherty, John F. | Flaherty, JF | 15 | Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Gaggar, Anuj | Gaggar, A | 16 | Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Suri, Vithika | Suri, V | 17 | Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Tan, Susanna | Tan, S | 18 | Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Liu, Yang | Liu, Y | 19 | Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Wu, George | Wu, G | 20 | Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA | pietro.lampertico@unimi.it; | |||||
| A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results | Subramanian, Mani | Subramanian, M | 21 | Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA | pietro.lampertico@unimi.it; |
페이지 이동: